Hurst DP - Search Results

1

Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.

Ragusa G, Bencivenni S, Morales P, Callaway T, Hurst DP, Asproni B, Merighi S, Loriga G, Pinna GA, Reggio PH, Gessi S, Murineddu G. Ragusa G, et al. Among authors: hurst dp. ChemMedChem. 2018 Jun 6;13(11):1102-1114. doi: 10.1002/cmdc.201800152. Epub 2018 Apr 16. ChemMedChem. 2018. PMID: 29575721

2

Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories.

Barnett-Norris J, Guarnieri F, Hurst DP, Reggio PH. Barnett-Norris J, et al. Among authors: hurst dp. J Med Chem. 1998 Nov 19;41(24):4861-72. doi: 10.1021/jm9803471. J Med Chem. 1998. PMID: 9822555

3

The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.

Reggio PH, Basu-Dutt S, Barnett-Norris J, Castro MT, Hurst DP, Seltzman HH, Roche MJ, Gilliam AF, Thomas BF, Stevenson LA, Pertwee RG, Abood ME. Reggio PH, et al. Among authors: hurst dp. J Med Chem. 1998 Dec 17;41(26):5177-87. doi: 10.1021/jm9801197. J Med Chem. 1998. PMID: 9857088

4

Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity.

Tao Q, McAllister SD, Andreassi J, Nowell KW, Cabral GA, Hurst DP, Bachtel K, Ekman MC, Reggio PH, Abood ME. Tao Q, et al. Among authors: hurst dp. Mol Pharmacol. 1999 Mar;55(3):605-13. Mol Pharmacol. 1999. PMID: 10051546

5

The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2).

Song ZH, Slowey CA, Hurst DP, Reggio PH. Song ZH, et al. Among authors: hurst dp. Mol Pharmacol. 1999 Oct;56(4):834-40. Mol Pharmacol. 1999. PMID: 10496968

6

Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor.

Barnett-Norris J, Hurst DP, Lynch DL, Guarnieri F, Makriyannis A, Reggio PH. Barnett-Norris J, et al. Among authors: hurst dp. J Med Chem. 2002 Aug 15;45(17):3649-59. doi: 10.1021/jm0200761. J Med Chem. 2002. PMID: 12166938

7

N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.

Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, Reggio PH. Hurst DP, et al. Mol Pharmacol. 2002 Dec;62(6):1274-87. doi: 10.1124/mol.62.6.1274. Mol Pharmacol. 2002. PMID: 12435794

8

Activation of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch.

Singh R, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Guarnieri F. Singh R, et al. Among authors: hurst dp. J Pept Res. 2002 Dec;60(6):357-70. doi: 10.1034/j.1399-3011.2002.21065.x. J Pept Res. 2002. PMID: 12464114

9

3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor.

Huffman JW, Mabon R, Wu MJ, Lu J, Hart R, Hurst DP, Reggio PH, Wiley JL, Martin BR. Huffman JW, et al. Among authors: hurst dp. Bioorg Med Chem. 2003 Feb 20;11(4):539-49. doi: 10.1016/s0968-0896(02)00451-0. Bioorg Med Chem. 2003. PMID: 12538019

10

An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Abood ME. McAllister SD, et al. Among authors: hurst dp. J Med Chem. 2003 Nov 20;46(24):5139-52. doi: 10.1021/jm0302647. J Med Chem. 2003. PMID: 14613317

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters